Top-Rated StocksTop-RatedNASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free AXSM Stock Alerts $79.17 +2.45 (+3.19%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$74.53▼$79.2550-Day Range$69.39▼$97.6452-Week Range$55.02▼$98.40Volume484,774 shsAverage Volume900,885 shsMarket Capitalization$3.75 billionP/E RatioN/ADividend YieldN/APrice Target$119.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Axsome Therapeutics alerts: Email Address Axsome Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside51.2% Upside$119.67 Price TargetShort InterestBearish15.41% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.45Based on 24 Articles This WeekInsider TradingSelling Shares$2.09 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.71) to $1.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.84 out of 5 starsMedical Sector45th out of 939 stocksPharmaceutical Preparations Industry19th out of 435 stocks 4.4 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $119.67, Axsome Therapeutics has a forecasted upside of 51.2% from its current price of $79.17.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.41% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 2.28%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 2.5 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Axsome Therapeutics this week, compared to 6 articles on an average week.Search Interest24 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 19 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -34% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,089,327.00 in company stock.Percentage Held by Insiders24.50% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($3.71) to $1.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -15.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -15.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 19.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Axsome Therapeutics Stock (NASDAQ:AXSM)Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Stock News HeadlinesMarch 16, 2024 | insidertrades.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Director Roger Jeffs Sells 29,976 SharesMarch 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Axsome Therapeutics: Diverse Portfolio and Market Potential Despite ChallengesMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 27, 2024 | investorplace.com3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch ListMarch 27, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $190.00 at HC WainwrightMarch 27, 2024 | americanbankingnews.comAxsome Therapeutics' (AXSM) "Buy" Rating Reaffirmed at Truist FinancialMarch 27, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Increased to $127.00 by Analysts at CitigroupMarch 27, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Increased to $128.00 by Analysts at Royal Bank of CanadaMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 26, 2024 | markets.businessinsider.comMaintaining Hold on Axsome Therapeutics: Weighing AXS-12’s Modest Efficacy Against Competitive and Market RisksMarch 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE)March 25, 2024 | msn.comWhat's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?March 25, 2024 | globenewswire.comAxsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 PatientsMarch 25, 2024 | reuters.comAxsome Therapeutics sleep disorder therapy succeeds in late-stage trialMarch 25, 2024 | globenewswire.comAxsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in NarcolepsyMarch 23, 2024 | finance.yahoo.comBuying These Dirt-Cheap Stocks Could Be a Brilliant MoveMarch 23, 2024 | fool.comBuying These Dirt-Cheap Stocks Could Be a Brilliant MoveMarch 22, 2024 | finance.yahoo.comAxsome Triumphs Over Major Depressive Disorder With AuvelityMarch 21, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Axsome Therapeutics (NASDAQ:AXSM)March 21, 2024 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from AnalystsMarch 21, 2024 | americanbankingnews.comRobert W. Baird Initiates Coverage on Axsome Therapeutics (NASDAQ:AXSM)March 19, 2024 | msn.comBaird starts Axsome at outperform, cites upcoming dataMarch 19, 2024 | finanznachrichten.deAxsome Therapeutics, Inc.: Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderMarch 19, 2024 | investing.comBaird starts Axsome Therapeutics stock at Outperform on promising trial outlookMarch 19, 2024 | markets.businessinsider.comAxsome Therapeutics Gains After Initiation Of Paradigm Phase 3 Trial Of SolriamfetolMarch 19, 2024 | markets.businessinsider.comAxsome Therapeutics’ Auvelity Rebounds: A Buy Rating Reinforced by Prescription Growth and Market ResilienceMarch 19, 2024 | globenewswire.comAxsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderSee More Headlines Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees545Year FoundedN/APrice Target and Rating Average Stock Price Target$119.67 High Stock Price Target$190.00 Low Stock Price Target$81.00 Potential Upside/Downside+51.2%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($5.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-239,240,000.00 Net Margins-88.41% Pretax Margin-88.06% Return on Equity-70.67% Return on Assets-27.47% Debt Debt-to-Equity Ratio0.93 Current Ratio3.63 Quick Ratio3.52 Sales & Book Value Annual Sales$270.60 million Price / Sales13.86 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book19.60Miscellaneous Outstanding Shares47,370,000Free Float35,767,000Market Cap$3.75 billion OptionableOptionable Beta1.17 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Herriot Tabuteau M.D. (Age 56)Founder, Chairman, CEO & President Comp: $1.32MMr. Nick Pizzie CPA (Age 49)M.B.A., Chief Financial Officer Comp: $732.94kMr. Mark L. Jacobson (Age 41)COO & Secretary Comp: $784.66kMr. Hunter Murdock Esq. (Age 44)General Counsel & Secretary Comp: $735.39kDr. Amanda Jones Pharm.D. (Age 41)Senior Vice President of Clinical Development Ms. Lori Englebert M.B.A. (Age 46)Executive Vice President of Commercial & Business Development Joseph Debrah-Afful CPAM.B.A., Director of FinanceMore ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCPrestige Consumer HealthcareNYSE:PBHCymaBay TherapeuticsNASDAQ:CBAYUltragenyx PharmaceuticalNASDAQ:RAREArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsRoger JeffsSold 29,976 sharesTotal: $2.09 M ($69.70/share)Vanguard Group Inc.Sold 32,360 shares on 3/11/2024Ownership: 7.804%Wellington Management Group LLPBought 2,265 shares on 3/5/2024Ownership: 0.506%American International Group Inc.Bought 162 shares on 2/28/2024Ownership: 0.037%Perceptive Advisors LLCBought 556,370 shares on 2/26/2024Ownership: 2.194%View All Insider TransactionsView All Institutional Transactions AXSM Stock Analysis - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price target for 2024? 13 brokers have issued 1-year price objectives for Axsome Therapeutics' shares. Their AXSM share price targets range from $81.00 to $190.00. On average, they predict the company's stock price to reach $119.67 in the next year. This suggests a possible upside of 51.2% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2024? Axsome Therapeutics' stock was trading at $79.59 on January 1st, 2024. Since then, AXSM stock has decreased by 0.5% and is now trading at $79.17. View the best growth stocks for 2024 here. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AXSM earnings forecast. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($1.21) by $0.48. The company earned $71.53 million during the quarter, compared to analysts' expectations of $70.38 million. Axsome Therapeutics had a negative net margin of 88.41% and a negative trailing twelve-month return on equity of 70.67%. What ETFs hold Axsome Therapeutics' stock? ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has Axsome Therapeutics issued on next quarter's earnings? Axsome Therapeutics updated its fourth quarter 2023 earnings guidance on Thursday, January, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $71.0 million-$71.0 million, compared to the consensus revenue estimate of $66.4 million. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.81%), Vanguard Group Inc. (7.80%), BVF Inc. IL (4.19%), Perceptive Advisors LLC (2.19%), Point72 Asset Management L.P. (1.77%) and Bellevue Group AG (1.34%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXSM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.